Stockreport

Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III

IPSEN SA S/ADR  (IPSEY) 
NASDAQ:AMEX Investor Relations: ipsen.com/investors
PDF IPN10200 is a recombinant, first-in-class molecule uniquely engineered to generate increased receptor affinity and internalization that produces a longer duration of act [Read more]